ClinicalTrials.gg
CompletedNCT02214433Updated Feb 25, 2015

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

A Phase 1 interventional study of Placebo IV Solution and Debio 1450 IV Solution in Bacterial Infections, sponsored by Debiopharm International SA. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-25.

Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Enrollment
71st of 151
70 · median 62
Started
2014
with 11 others
Phase 1
66 of 181
2 open now
Registered
83rd of 181
by date
Lead sponsor
3 of 181
Debiopharm International SA

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 71st largest by enrollment of the 151 interventional ones that give a count, is one of 12 that started in 2014, is one of 66 in phase 1, and was the 83rd registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

Debio 1450-103 is a trial to study the pharmacokinetics (PK) of an experimental drug called Debio 1450 in healthy adult volunteers. Originally, Part A was registered separately (in NCT02214355). The registrations have been revised so all parts of this single trial (Parts A-C) are now included in this single registration (NCT02214433).

The primary purpose of each part is provided below:

  • 10 volunteers participate in PART A to assess the PK of a single oral dose of Debio 1450 (tablet formulation) under varying gastric conditions
  • 40 volunteers participate in PART B to assess the safety, tolerability and PK of multiple ascending doses of Debio 1450, administered sequentially IV and orally, once or twice daily.
  • An additional 10 volunteers participate in PART C which is designed to assess the absolute bioavailability of various formulations of Debio 1450 under varying gastric conditions

The dose administered during Part A is based on the safety, tolerability and PK data from study Debio 1450-102 [NCT02162199], a single ascending dose (SAD) study, in which single oral doses up to 800 mg/day are being investigated. Doses are adjusted during Parts B and C based on the available safety and PK data from preceding cohorts.

03

Conditions studied

  • Bacterial Infections

Browse trials for

Keywords

  • Antibiotic
  • Antibiotic Resistant Bacterial Infection
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets protocol-specified criteria for qualification and/or
  • Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related to food, drink and medications
  • Voluntarily consents to participate and provides written prior to any protocol-specific procedures

Exclusion criteria

Exclusion Criteria:

  • Has a history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters
  • Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:

    1. the safety or well-being of the participant or study staff
    2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
    3. the analysis of results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Part A Period 1 Debio 1450 IV Solution

    Part A Debio 1450 IV solution infused over two hours on Day 1 after fasting

    Drug: Debio 1450 IV Solution

  • Experimental
    Part A Period 2 Debio 1450 Tablet

    Debio 1450 Tablet oral dosing once on Day 5, after fasting

    Drug: Debio 1450 Tablet

  • Experimental
    Part A Period 3 Debio 1450 Tablet

    Debio 1450 Tablet oral dosing once on Day 9, 30 minutes after a high calorie, high fat breakfast, after fasting

    Drug: Debio 1450 Tablet

  • Experimental
    Part A Period 4 Debio 1450 Tablet

    After preparation with Pantoprazole, Pantoprazole taken with Debio 1450 Tablet oral dosing once on Day 14, after fasting

    Drug: Debio 1450 Tablet · Drug: Pantoprazole

  • Placebo comparator
    Part B Placebo All Cohorts

    Placebo IV solution on days 1-5 and then Placebo Tablet or Capsule on Days 6-10, according to the cohort dosing schedule

    Drug: Placebo IV Solution · Drug: Placebo Tablet or Capsule

  • Experimental
    Part B Debio 1450 Cohort 1

    Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Tablet, once daily on days 6-10

    Drug: Debio 1450 IV Solution · Drug: Debio 1450 Tablet

  • Experimental
    Part B Debio 1450 Cohort 2a

    Debio 1450 IV solution, once daily on day 1

    Drug: Debio 1450 IV Solution

  • Experimental
    Part B Debio 1450 Cohort 3

    Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10

    Drug: Debio 1450 IV Solution · Drug: Debio 1450 Capsule

  • Experimental
    Part B Debio 1450 Cohort 4

    Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10

    Drug: Debio 1450 IV Solution · Drug: Debio 1450 Capsule

  • Experimental
    Part B Debio 1450 Cohort 2b

    Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Capsule, once daily on days 6-10

    Drug: Debio 1450 IV Solution · Drug: Debio 1450 Capsule

  • Experimental
    Part C Debio 1450

    Debio 1450 (IV formulation in Period 1, capsule formulation in Periods 2, 4 and 5 (with Pantoprazole), and Debio 1450 oral solution in Period 3).

    Drug: Debio 1450 IV Solution · Drug: Debio 1450 Capsule · Drug: Debio 1450 Oral Solution · Drug: Pantoprazole

Interventions

  • DrugPlacebo IV Solution

    A sterile IV solution of 5% dextrose in water

  • A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water

  • DrugPlacebo Tablet or Capsule

    Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule

  • Debio 1450 40 mg coated tablets

  • Debio 1450 40 mg capsules

  • Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water

  • Pantoprazole 40 mg orally

06

What researchers measure

Primary outcomes

  1. Number of participants with clinically significant change from baseline in safety parameters

    Categories: vital signs, 12-lead electrocardiogram (ECG), clinical laboratory parameters, adverse events, pulmonary function, physical examination, concomitant medication

    Time frame: within 10 days post-dose

  2. Maximum observed plasma concentration (Cmax) of Debio 1450 (prodrug) and Debio 1452 (active moiety)

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  3. Time of maximum observed plasma concentration (tmax) of Debio 1450 and Debio 1452

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  4. Area under the plasma concentration-time curve (AUC) of Debio 1450 and Debio 1452

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  5. Percentage of AUC(0-o) that is due to extrapolation beyond the last quantifiable concentration measurement (%AUCex) of Debio 1450 and Debio 1452

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  6. Elimination half-life (t1/2) of Debio 1450 and Debio 1452

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  7. Terminal elimination rate constant (Az) of Debio 1450 and Debio 1452

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  8. Mean residence time (MRT) of Debio 1450 and Debio 1452

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  9. Apparent clearance following oral administration (CL/F) of Debio 1450 and Debio 1452

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  10. Apparent volume of distribution of Debio 1450 and Debio 1452 during terminal phase (Vz/F)

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  11. Cumulative amount of unchanged Debio 1450 and Debio 1452 excreted in urine (Ae)

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  12. Percentage of cumulative amount of unchanged Debio 1450 and Debio 1452 excreted in urine (Ae%)

    Categories: Placebo Tablet or Capsule, Placebo IV Solution, Debio 1450 IV solution, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

  13. Renal clearance following oral administration

    Categories: Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 oral solution

    Time frame: within 60 hours post-dose, depending on the assessment schedule for the cohort

07

Study locations

1 site
  • Early Phase Clinical Unit
    Baltimore, Maryland 21225, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2014
First posted
Aug 12, 2014
Start
Aug 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Feb 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02214433
Responsible party
Sponsor
First posted
Aug 12, 2014
Start date
Aug 2014
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Feb 25, 2015

Study contacts

Frederick Wittke, MD
study director · Debiopharm International SA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Afabicin · Pantoprazole

Start the discussion